Non‑nucleoside inhibitors of SARS‑CoV‑2 RdRp identified by high‑throughput screening and an approach to their mechanism of action by comparative studies
The findings expand the repertoire of NNIs against SARS-CoV-2 RdRp, establish a unified framework for comparative evaluation of RdRp inhibitors, and provide insights into the differential impacts of the NNIs on RdRp-RNA complex formation, thereby supporting future development of allosteric antiviral therapeutics.